A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy

Lung Cancer

Volumn 86, Issue 2, 2014, Pages 288-290

  Weiss, Jared M ^a   Villaruz, Liza C ^a   Socinski, Mark A ^a   Ivanova, Anastasia ^a   Grilley Olson, Juneko ^a   Dhruva, Nirav ^a   Stinchcombe, Thomas E ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Angiogenesis; Clinical trial; Multi targeted tyrosine kinase inhibitors; Non small cell lung cancer; Second line therapy; Targeted therapy

Indexed keywords

BEVACIZUMAB; PAZOPANIB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; ADVANCED CANCER; ADVERSE DRUG REACTION; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE CONTROL; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; HISTOLOGY; HUMAN; HYPERTENSION; INFECTION; MALE; MUCOSA INFLAMMATION; NAUSEA; NON SMALL CELL LUNG CANCER; NON SQUAMOUS NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE COURSE; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84908897487     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.08.011     Document Type: Article

References (19)

1. Siegel B.A., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29.
2. Soerjomataram I., Lortet-Tieulent J., Parkin D.M., Ferlay J., Mathers C., Forman D., et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012, 380(9856):1840-1850.
3. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27(36):6251-6266.
4. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crino L., Ahn M.J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368(25):2385-2394.
5. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
6. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010, 21(9):1804-1809.
7. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27(8):1227-1234.
8. Vasudev N.S., Reynolds A.R. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 2014, 17(3):471-494.
9. Altorki N., Lane M.E., Bauer T., Lee P.C., Guarino M.J., Pass H., et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 2010, 28(19):3131-3137.
10. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247.
11. [accessed 28.04.14]. http://www.clinicaltrials.gov/ct2/show/NCT01208064.
12. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
13. Scagliotti G.V., Krzakowski M., Szczesna A., Strausz J., Makhson A., Reck M., et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 2012, 30(17):2070-2078.
14. Scagliotti G.V., Vynnychenko I., Park K., Ichinose Y., Kubota K., Blackhall F., et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 2012, 30(23):2829-2836.
15. Scagliotti G., Novello S., von Pawel J., Reck M., Pereira J.R., Thomas M., et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(11):1835-1842.
16. Herbst R.S., Sun Y., Eberhardt W.E., Germonpre P., Saijo N., Zhou C., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010, 11(7):619-626.
17. Reck M., Kaiser R., Mellemgaard A., Douillard J.Y., Orlov S., Krzakowski M., et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014, 15(2):143-155.
18. Hanna N.H., Kaiser R., Sullivan R.N., Aren O.R., Ahn M.-J., Tiangco B., et al. Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 2013, 31(Suppl.). [abstract 8034].
19. de Boer R.H., Arrieta O., Yang C.H., Gottfried M., Chan V., Raats J., et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011, 29(8):1067-1074.